On May 3, 2016, Miroculus, a San Francisco-based biotechnology company specializing in microRNA-based diagnostics, announced its acquisition of Toronto-based Kapplex Inc., pursuant to which Kapplex has become Miroculus’ Canadian subsidiary.
Kapplex is a startup developing sensitive, high-performance and multiplexed point-of-care diagnostic platforms suitable for use in doctor’s offices, urgent care, and emergency rooms to enable clinicians to rapidly and accurately diagnose a disease at a patient’s first visit and significantly improve the course of treatment while reducing healthcare costs.
Miller Thomson advised Kapplex with a team that was led by Robert Stewart and that included Max Spearn and Corey Yermus (corporate/M&A) and Gerald Courage (tax), assisted by student-at-law Gary Volman.
